Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas

JAMA Otolaryngology - Head and Neck Surgery

Volumn 139, Issue 10, 2013, Pages 1026-1031

  Thaivalappil, Silpa ^a   Bauman, Nancy ^a,b   Saieg, Amarel ^a   Movius, Elizabeth ^a   Brown, Kristy J ^a   Preciado, Diego ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PREDNISOLONE; PROPRANOLOL;

ARTICLE; CAPILLARY HEMANGIOMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEWBORN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PROTEIN CONTENT; PROTEOMICS; URINALYSIS;

EID: 84892421256     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.4773     Document Type: Article

References (20)

1. Buckmiller LM. Update on hemangiomas and vascular malformations. Curr Opin Otolaryngol Head Neck Surg. 2004;12(6):476-487.
2. Blei F. Basic science and clinical aspects of vascular anomalies. Curr Opin Pediatr. 2005;17(4):501-509.
3. Chang LC, Haggstrom AN, Drolet BA, et al Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367.
4. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(6):2357-2364.
5. Zhang L, Lin X,Wang W, et al. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg. 2005;116(1):200-204.
6. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119(6):e1239-e1247.
7. Dosquet C, Coudert MC,Wassef M, Enjolras O, Drouet L. Importance of bFGF ("basic fibroblast growth factor") for diagnosis and treatment of hemangiomas [in French]. Ann Dermatol Venereol. 1998;125(5):313-316.
8. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. 2000;105(1, pt 1):117-120.
9. Marler JJ, Fishman SJ, Kilroy SM, et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics. 2005;116(1):38-45.
10. Starkey E, Shahidullah H. Propranolol for infantile haemangiomas: a review. Arch Dis Child. 2011;96(9):890-893.
11. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-1213.
12. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651.
13. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359(26):2846-2847.
14. Jensen ON, Wilm M, Shevchenko A, Mann M. Sample preparationmethods for mass spectrometric peptide mapping directly from 2-DE gels. Methods Mol Biol. 1999;112:513-530.
15. Preciado D, Goyal S, Rahimi M, et al. MUC5B Is the predominant mucin glycoprotein in chronic otitis media fluid. Pediatr Res. 2010;68(3):231-236.
16. Annabi B, LachambreMP, Plouffe K, Moumdjian R, Béliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res. 2009;60(5):438-445.
17. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26(4):716-728.
18. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269-274.
19. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem. 2007;282(52):37585- 37596.
20. Bellini T, Trentini A, Manfrinato MC, et al. Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms. J Biochem. 2012;151(5):493-499.